Maina Bhaman
Director/Board Member bij Kesios Therapeutics Ltd.
Profiel
Maina Bhaman is currently a Director at Kesios Therapeutics Ltd., ENYO Pharma SA, Mironid Ltd., Sitryx Therapeutics Ltd., Mediar Therapeutics, Inc., Catamaran Bio, Inc., Myricx Pharma Ltd., Sofinnova Partners SAS, and Touchstone Innovations Businesses LLP.
Dr. Bhaman's former positions include being a Director-Healthcare Investments at Touchstone Innovations Ltd., a Non-Independent Non-Executive Director at Ixico Plc, a Non-Executive Director at The Acrobot Co. Ltd., a Director at Touchstone Innovations Investment Management Ltd., a Non-Executive Director at Molecular Vision Ltd., a Non-Executive Director at IXICO Ltd., a Director at Kuur Therapeutics Ltd., a Non-Executive Director at Akamis Bio Ltd., a Director at Autifony Therapeutics Ltd., a Director at Topivert Pharma Ltd., a Director at CalciCo Therapeutics Ltd., a Director at CinCor Pharma, Inc., a Senior Scientist at Celltech Group Plc, a Principal at Oxford GlycoSciences Plc, and a Principal at Chimeric Therapies, Inc. Dr. Bhaman completed an undergraduate degree at The University of Texas at Austin and holds an MBA from Imperial College Business School.
Actieve functies van Maina Bhaman
Bedrijven | Functie | Begin |
---|---|---|
Touchstone Innovations Businesses LLP
Touchstone Innovations Businesses LLP Investment ManagersFinance Touchstone Innovations Businesses LLP commercializes academic research and technology businesses. The company was founded on December 19, 2007 and is headquartered in London, the United Kingdom. | Corporate Officer/Principal | 14-01-2008 |
Kesios Therapeutics Ltd.
Kesios Therapeutics Ltd. BiotechnologyHealth Technology Kesios Therapeutics Ltd. provides biotechnology services. It develops novel therapeutics for the treatment of multiple myeloma and other cancers where there are significant unmet medical needs. The company was founded by Menotti Ruvo, Laura Tornatore, and Guido Franzoso on July 13, 2012 and is headquartered in Cambridge, the United Kingdom. | Director/Board Member | - |
Sofinnova Partners SAS
Sofinnova Partners SAS Investment ManagersFinance Sofinnova Partners SA (Sofinnova) is an independent venture capital firm established in 1972 and headquartered in Paris, France. Originally known as Sofinnova, the first venture capital firm created in France, the firm created a U.S. subsidiary in San Francisco in 1976. In 1997, both firms were bought out by their management teams, which become the majority shareholders of the new companies, Sofinnova Partners in Paris and Sofinnova Ventures in San Francisco. | Private Equity Investor | 01-01-2018 |
Sitryx Therapeutics Ltd.
Sitryx Therapeutics Ltd. Medical SpecialtiesHealth Technology Sitryx Therapeutics Ltd. Focuses on regulating cell metabolism to develop disease-modifying therapeutics in immuno-oncology and immuno-inflammation. It treats cancer and inflammatory conditions by targeting the metabolism of immune cells. The company was founded by Houman Ashrafian, Paul-Peter Tak, Luke O'Neill, Jonathan Powell, Jeff Rathmell and Michael Rosenblum and is headquartered in London, the United Kingdom. | Director/Board Member | - |
Myricx Pharma Ltd.
Myricx Pharma Ltd. Miscellaneous Commercial ServicesCommercial Services Myricx Pharma Ltd. engages in the development of novel proprietary inhibitors of human N-myristoyltransferases. The company was founded by Ed Tate, Roberto Solari, and Andrew Bell in 2019 and is headquartered in Stevenage, the United Kingdom. | Director/Board Member | - |
Catamaran Bio, Inc.
Catamaran Bio, Inc. Financial ConglomeratesFinance Catamaran Bio, Inc. provides investment services. The company is headquartered in Delaware. | Director/Board Member | - |
ENYO Pharma SA
ENYO Pharma SA BiotechnologyHealth Technology ENYO Pharma SA operates as a biopharmaceutical company. The firm's research and development is focused on human infecting viruses, with the first two programs being dedicated to the treatment of severe and seasonal flu and chronic hepatitis B. The company was founded by Jacky Vonderscher, Jean-Jacques Garaud, Benoît de Chassey, Laurène Meyniel-Schicklin, Patrice André and Vincent Lotteau January 2014 and is headquartered in Lyon, France. | Director/Board Member | - |
Mironid Ltd.
Mironid Ltd. Pharmaceuticals: MajorHealth Technology Mironid Ltd. develops proprietary drug candidate molecules by modulating the activity of key cell signalling proteins. The company was founded by Miles Houslay, Paul Barton Rodgers, Elizabeth Fairley, Julia Adam, David Adams and Nigel Pyne in 2014 and is headquartered in North Lanarkshire, the United Kingdom. | Director/Board Member | - |
Mediar Therapeutics, Inc.
Mediar Therapeutics, Inc. BiotechnologyHealth Technology Mediar Therapeutics, Inc. develops therapeutics to halt, reverse and fibrosis. The company was founded by Paul Yaworsky in 2018 and is headquartered in Cambridge, MA. | Director/Board Member | 15-03-2023 |
Eerdere bekende functies van Maina Bhaman
Bedrijven | Functie | Einde |
---|---|---|
░░░░░░ ░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ |
░░░░░░░░░░ ░░░░░░░░░░░ ░░░░░░░░░░ ░░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ |
░░░░░░░░ ░░░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ |
░░░░░░░░░░ ░░░░░░░░░░░ ░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
░░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ |
Opleiding van Maina Bhaman
The University of Texas at Austin | Undergraduate Degree |
Imperial College Business School | Masters Business Admin |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
Beursgenoteerde bedrijven | 1 |
---|---|
IXICO PLC | Commercial Services |
Bedrijven in privébezit | 23 |
---|---|
Celltech Group Plc
Celltech Group Plc BiotechnologyHealth Technology Celltech Group Plc was one of the leading European biotechnology company which is engaged in discovery and development of innovative drugs. The company was located in Slough, United Kingdom. | Health Technology |
Touchstone Innovations Ltd.
Touchstone Innovations Ltd. Investment ManagersFinance Touchstone Innovations Ltd. engages in the provision of technology and commercialization services. The company was founded by Susan Jane Searle in 1986 and is headquartered in London, the United Kingdom. | Finance |
Sofinnova Partners SAS
Sofinnova Partners SAS Investment ManagersFinance Sofinnova Partners SA (Sofinnova) is an independent venture capital firm established in 1972 and headquartered in Paris, France. Originally known as Sofinnova, the first venture capital firm created in France, the firm created a U.S. subsidiary in San Francisco in 1976. In 1997, both firms were bought out by their management teams, which become the majority shareholders of the new companies, Sofinnova Partners in Paris and Sofinnova Ventures in San Francisco. | Finance |
Oxford GlycoSciences Plc
Oxford GlycoSciences Plc Pharmaceuticals: MajorHealth Technology Oxford Glycosciences Plc provides biopharmaceutical products. The company develops and manufactures novel products for the diagnosis and treatment of human disease. Its products include bayer, pioneer hi-breddupont, medarex, genmab, glaxosmithkline, neogenesis and pfizer. It was founded in 1988. The company is headquartered in Abingdon, UK. | Health Technology |
The Acrobot Co. Ltd.
The Acrobot Co. Ltd. Medical SpecialtiesHealth Technology The Acrobot Co. Ltd. develops precision surgical systems for minimally invasive, bone conserving and orthopedic surgery. It also assists surgeons in achieving better patient outcomes by improving surgical precision and reducing surgical errors. The company was founded by Brian Davies and Justin Cobb in 1999 and is headquartered in London, GB. | Health Technology |
Touchstone Innovations Investment Management Ltd.
Touchstone Innovations Investment Management Ltd. Investment ManagersFinance Touchstone Innovations Investment Management Ltd. is a Venture Capital firm, a subsidiary of Touchstone Innovations Ltd. founded in 1986. Touchstone Innovations Investment Management Ltd. is headquartered in London. | Finance |
Molecular Vision Ltd.
Molecular Vision Ltd. Medical SpecialtiesHealth Technology Molecular Vision Ltd. develops low-cost, lab-quality, point of care, disposable diagnostic devices for medical testing. The company was founded by Donal D. C. Bradley in 2001 and is headquartered in York, the United Kingdom. | Health Technology |
Chimeric Therapies, Inc. | |
IXICO Ltd.
IXICO Ltd. Medical/Nursing ServicesHealth Services IXICO Ltd. operates as a medical imaging company that provides imaging biomarkers for clinical trials, research studies and diagnostics. It offers web-based interface services providing researchers instant visibility of the imaging trial progress in real time, and enabling the tracking of imaging information against predefined study milestones such as study compliance or image quality. The company was founded by Derek Hill, Jo Hajnal, David Hawkes and Daniel Rueckert in December 2004 and is headquartered in London, GB. | Health Services |
Kuur Therapeutics Ltd.
Kuur Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Kuur Therapeutics provides clinical cellular therapeutics services. It develops, manufactures and markets personalized cellular immunotherapeutics for infectious disease and cancer. Cell Medica has developed proprietary production technology enabling GMP compliant manufacture of antigen-specific T cells. The company was founded by Gregg Sando in 2006 and is headquartered in London, the United Kingdom. | Health Technology |
Touchstone Innovations Businesses LLP
Touchstone Innovations Businesses LLP Investment ManagersFinance Touchstone Innovations Businesses LLP commercializes academic research and technology businesses. The company was founded on December 19, 2007 and is headquartered in London, the United Kingdom. | Finance |
Akamis Bio Ltd.
Akamis Bio Ltd. BiotechnologyHealth Technology Akamis Bio Ltd. operates as a biotechnology company which develops novel therapeutics that addresses cancer and other clinically unmet diseases. Its products include Enadenotucirev, Espindolol and AbEnAd. The firm also develops treatments based upon the research phase vaccine platform PolySTAR, which combines recombinant viral vectors with polymers to shield them from the immune system, and the research phase adjuvant and immunotherapeutic platform PolyMAP, which combines polymers with synthetic adjuvants to significantly enhance the effectiveness of vaccines. The company was founded by Andrew Justin Stewart Coats and Stefan D. Anker on November 17, 2006 and is headquartered in Abingdon, the United Kingdom. | Health Technology |
Autifony Therapeutics Ltd.
Autifony Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Autifony Therapeutics Ltd. discovers and develops new pharmaceutical treatments treat hearing disorders. The firm focuses on the treatment of hearing disorders, including noise-induced hearing loss and tinnitus. The company was founded by Charles H. Large and Giuseppe S. Alvaro in 2011 and is headquartered in London, the United Kingdom. | Health Technology |
Topivert Pharma Ltd.
Topivert Pharma Ltd. Pharmaceuticals: MajorHealth Technology Topivert Pharma Ltd. is a British pharmaceutical company founded in 2011. The private company develops non-systemic medicines for the treatment of chronic inflammatory diseases of the gastrointestinal. | Health Technology |
Kesios Therapeutics Ltd.
Kesios Therapeutics Ltd. BiotechnologyHealth Technology Kesios Therapeutics Ltd. provides biotechnology services. It develops novel therapeutics for the treatment of multiple myeloma and other cancers where there are significant unmet medical needs. The company was founded by Menotti Ruvo, Laura Tornatore, and Guido Franzoso on July 13, 2012 and is headquartered in Cambridge, the United Kingdom. | Health Technology |
ENYO Pharma SA
ENYO Pharma SA BiotechnologyHealth Technology ENYO Pharma SA operates as a biopharmaceutical company. The firm's research and development is focused on human infecting viruses, with the first two programs being dedicated to the treatment of severe and seasonal flu and chronic hepatitis B. The company was founded by Jacky Vonderscher, Jean-Jacques Garaud, Benoît de Chassey, Laurène Meyniel-Schicklin, Patrice André and Vincent Lotteau January 2014 and is headquartered in Lyon, France. | Health Technology |
Mironid Ltd.
Mironid Ltd. Pharmaceuticals: MajorHealth Technology Mironid Ltd. develops proprietary drug candidate molecules by modulating the activity of key cell signalling proteins. The company was founded by Miles Houslay, Paul Barton Rodgers, Elizabeth Fairley, Julia Adam, David Adams and Nigel Pyne in 2014 and is headquartered in North Lanarkshire, the United Kingdom. | Health Technology |
CalciCo Therapeutics Ltd.
CalciCo Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology CalciCo Therapeutics Ltd. develops novel small molecule drugs for autoimmune and inflammatory disorders. The company was founded by Anant Parekh and is headquartered in Oxford, the United Kingdom. | Health Technology |
Sitryx Therapeutics Ltd.
Sitryx Therapeutics Ltd. Medical SpecialtiesHealth Technology Sitryx Therapeutics Ltd. Focuses on regulating cell metabolism to develop disease-modifying therapeutics in immuno-oncology and immuno-inflammation. It treats cancer and inflammatory conditions by targeting the metabolism of immune cells. The company was founded by Houman Ashrafian, Paul-Peter Tak, Luke O'Neill, Jonathan Powell, Jeff Rathmell and Michael Rosenblum and is headquartered in London, the United Kingdom. | Health Technology |
Mediar Therapeutics, Inc.
Mediar Therapeutics, Inc. BiotechnologyHealth Technology Mediar Therapeutics, Inc. develops therapeutics to halt, reverse and fibrosis. The company was founded by Paul Yaworsky in 2018 and is headquartered in Cambridge, MA. | Health Technology |
CinCor Pharma, Inc.
CinCor Pharma, Inc. Pharmaceuticals: MajorHealth Technology CinCor Pharma, Inc. operates as a clinical-stage biopharmaceutical company focused on developing its clinical candidate, CIN-107, for the treatment of hypertension and other cardio-renal diseases. The firm is developing CIN-107 for the treatment of multiple diseases where aldosterone plays a significant role in disease pathophysiology, including hypertension and primary aldosteronism, as well as its utility in ameliorating complications of chronic kidney disease. The company was founded by Jon Isaacsohn and Catherine Pearce on March 28, 2018 and is headquartered in Waltham, MA. | Health Technology |
Catamaran Bio, Inc.
Catamaran Bio, Inc. Financial ConglomeratesFinance Catamaran Bio, Inc. provides investment services. The company is headquartered in Delaware. | Finance |
Myricx Pharma Ltd.
Myricx Pharma Ltd. Miscellaneous Commercial ServicesCommercial Services Myricx Pharma Ltd. engages in the development of novel proprietary inhibitors of human N-myristoyltransferases. The company was founded by Ed Tate, Roberto Solari, and Andrew Bell in 2019 and is headquartered in Stevenage, the United Kingdom. | Commercial Services |